Identification

Name
Practolol
Accession Number
DB01297
Type
Small Molecule
Groups
Approved
Description

A beta-adrenergic antagonist that has been used in the emergency treatment of cardiac arrhythmias. [PubChem]

Structure
Thumb
Synonyms
  • (+-)-Practolol
  • 1-(4-Acetamidophenoxy)-3-isopropylamino-2-propanol
  • 4'-(2-Hydroxy-3-(isopropylamino)propoxy)acetanilide
  • N-(4-(2-Hydroxy-3-((1-methylethyl)amino)propoxy)phenyl)acetamide
  • Practololum
  • Tocris-0831
Product Ingredients
IngredientUNIICASInChI Key
Practolol hydrochlorideAT88RXS5AE6996-43-6UEWORNJBQXFYSM-UHFFFAOYSA-N
Categories
UNII
SUG9176GRW
CAS number
6673-35-4
Weight
Average: 266.3361
Monoisotopic: 266.16304258
Chemical Formula
C14H22N2O3
InChI Key
DURULFYMVIFBIR-UHFFFAOYSA-N
InChI
InChI=1S/C14H22N2O3/c1-10(2)15-8-13(18)9-19-14-6-4-12(5-7-14)16-11(3)17/h4-7,10,13,15,18H,8-9H2,1-3H3,(H,16,17)
IUPAC Name
N-(4-{2-hydroxy-3-[(propan-2-yl)amino]propoxy}phenyl)acetamide
SMILES
CC(C)NCC(O)COC1=CC=C(NC(C)=O)C=C1

Pharmacology

Indication

Used in the emergency treatment of cardiac arrhythmias.

Structured Indications
Not Available
Pharmacodynamics

Practolol is a beta-adrenergic receptor antagonist that has been used in the emergency treatment of cardiac arrhythmias. Beta blockers inhibit normal epinephrine-mediated sympathetic actions, but have minimal effect on resting subjects. That is, they reduce the effect of excitement/physical exertion on heart rate and force of contraction and dilation of blood vessels.

Mechanism of action

Like other beta-adrenergic antagonists, practolol competes with adrenergic neurotransmitters such as catecholamines for binding at sympathetic receptor sites. Like propranolol and timolol, practolol binds at beta(1)-adrenergic receptors in the heart and vascular smooth muscle, inhibiting the effects of the catecholamines epinephrine and norepinephrine and decreasing heart rate, cardiac output, and systolic and diastolic blood pressure.

TargetActionsOrganism
ABeta-1 adrenergic receptor
antagonist
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity

Symptoms of overdose include abdominal irritation, central nervous system depression, coma, extremely slow heartbeat, heart failure, lethargy, low blood pressure, and wheezing.

Affected organisms
Not Available
Pathways
PathwayCategory
Practolol Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-Phenanthroline1,10-Phenanthroline may increase the bradycardic activities of Practolol.Experimental
4-Methoxyamphetamine4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Practolol.Experimental, Illicit
AceclofenacAceclofenac may decrease the antihypertensive activities of Practolol.Approved, Investigational
AcemetacinAcemetacin may decrease the antihypertensive activities of Practolol.Approved
AcepromazineAcepromazine may increase the hypotensive activities of Practolol.Approved, Vet Approved
AceprometazineAceprometazine may increase the hypotensive activities of Practolol.Approved
AcetohexamidePractolol may increase the hypoglycemic activities of Acetohexamide.Investigational, Withdrawn
AcetylcholineThe risk or severity of adverse effects can be increased when Practolol is combined with Acetylcholine.Approved
AcetyldigitoxinPractolol may increase the bradycardic activities of Acetyldigitoxin.Approved
AcetyldigoxinPractolol may increase the bradycardic activities of Acetyldigoxin.Experimental
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Practolol.Approved, Vet Approved
AdapaleneAdapalene may decrease the antihypertensive activities of Practolol.Approved
AgmatineAgmatine may increase the atrioventricular blocking (AV block) activities of Practolol.Experimental, Investigational
AlaproclateThe serum concentration of Practolol can be increased when it is combined with Alaproclate.Experimental
AlclofenacAlclofenac may decrease the antihypertensive activities of Practolol.Approved, Withdrawn
AlfentanilAlfentanil may increase the bradycardic activities of Practolol.Approved, Illicit
AlfuzosinPractolol may increase the orthostatic hypotensive activities of Alfuzosin.Approved, Investigational
AlimemazineAlimemazine may increase the hypotensive activities of Practolol.Approved, Vet Approved
AlminoprofenAlminoprofen may decrease the antihypertensive activities of Practolol.Experimental
AmbenoniumAmbenonium may increase the bradycardic activities of Practolol.Approved
AmiodaroneAmiodarone may increase the bradycardic activities of Practolol.Approved, Investigational
AmobarbitalThe serum concentration of Practolol can be decreased when it is combined with Amobarbital.Approved, Illicit
AmodiaquineThe metabolism of Practolol can be decreased when combined with Amodiaquine.Approved, Investigational
AndrographolideAndrographolide may decrease the antihypertensive activities of Practolol.Investigational
AnisodamineAnisodamine may decrease the antihypertensive activities of Practolol.Investigational
AntipyrineAntipyrine may decrease the antihypertensive activities of Practolol.Approved
ApocyninApocynin may decrease the antihypertensive activities of Practolol.Investigational
ApomorphineApomorphine may increase the atrioventricular blocking (AV block) activities of Practolol.Approved, Investigational
ApremilastApremilast may decrease the antihypertensive activities of Practolol.Approved, Investigational
ArecolineThe risk or severity of adverse effects can be increased when Practolol is combined with Arecoline.Experimental
AzapropazoneAzapropazone may decrease the antihypertensive activities of Practolol.Withdrawn
AzelastineAzelastine may decrease the antihypertensive activities of Practolol.Approved
BalsalazideBalsalazide may decrease the antihypertensive activities of Practolol.Approved, Investigational
BarbexacloneThe serum concentration of Practolol can be decreased when it is combined with Barbexaclone.Experimental
BarbitalThe serum concentration of Practolol can be decreased when it is combined with Barbital.Illicit
BendazacBendazac may decrease the antihypertensive activities of Practolol.Experimental
BenorilateBenorilate may decrease the antihypertensive activities of Practolol.Experimental
BenoxaprofenBenoxaprofen may decrease the antihypertensive activities of Practolol.Withdrawn
BenzphetamineBenzphetamine may increase the atrioventricular blocking (AV block) activities of Practolol.Approved, Illicit
BethanecholThe risk or severity of adverse effects can be increased when Practolol is combined with Bethanechol.Approved
BethanidineBethanidine may increase the atrioventricular blocking (AV block) activities of Practolol.Approved
BevoniumBevonium may decrease the antihypertensive activities of Practolol.Experimental
BL-1020BL-1020 may increase the hypotensive activities of Practolol.Investigational
BrimonidineBrimonidine may increase the atrioventricular blocking (AV block) activities of Practolol.Approved
BromfenacBromfenac may decrease the antihypertensive activities of Practolol.Approved
BromocriptineBromocriptine may increase the atrioventricular blocking (AV block) activities of Practolol.Approved, Investigational
BucillamineBucillamine may decrease the antihypertensive activities of Practolol.Investigational
BucindololPractolol may increase the orthostatic hypotensive activities of Bucindolol.Investigational
BufexamacBufexamac may decrease the antihypertensive activities of Practolol.Experimental
BumadizoneBumadizone may decrease the antihypertensive activities of Practolol.Experimental
BunazosinPractolol may increase the orthostatic hypotensive activities of Bunazosin.Investigational
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Practolol.Approved, Investigational
CabergolinePractolol may increase the vasoconstricting activities of Cabergoline.Approved
CarbacholThe risk or severity of adverse effects can be increased when Practolol is combined with Carbachol.Approved
Carbaspirin calciumCarbaspirin calcium may decrease the antihypertensive activities of Practolol.Experimental, Investigational
CarbutamidePractolol may increase the hypoglycemic activities of Carbutamide.Experimental
CarprofenCarprofen may decrease the antihypertensive activities of Practolol.Approved, Vet Approved, Withdrawn
CarvedilolPractolol may increase the orthostatic hypotensive activities of Carvedilol.Approved, Investigational
CastanospermineCastanospermine may decrease the antihypertensive activities of Practolol.Experimental
CelecoxibCelecoxib may decrease the antihypertensive activities of Practolol.Approved, Investigational
CevimelineThe risk or severity of adverse effects can be increased when Practolol is combined with Cevimeline.Approved
ChloroquineThe metabolism of Practolol can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorproethazineChlorproethazine may increase the hypotensive activities of Practolol.Experimental
ChlorpromazineChlorpromazine may increase the hypotensive activities of Practolol.Approved, Vet Approved
ChlorpropamidePractolol may increase the hypoglycemic activities of Chlorpropamide.Approved
Choline magnesium trisalicylateCholine magnesium trisalicylate may decrease the antihypertensive activities of Practolol.Approved
ClonidineClonidine may increase the atrioventricular blocking (AV block) activities of Practolol.Approved
ClonixinClonixin may decrease the antihypertensive activities of Practolol.Approved
CoumaphosCoumaphos may increase the bradycardic activities of Practolol.Vet Approved
CurcuminCurcumin may decrease the antihypertensive activities of Practolol.Investigational
CymarinPractolol may increase the bradycardic activities of Cymarin.Experimental
D-LimoneneD-Limonene may decrease the antihypertensive activities of Practolol.Investigational
DapoxetineThe serum concentration of Practolol can be increased when it is combined with Dapoxetine.Investigational
DecamethoniumDecamethonium may increase the bradycardic activities of Practolol.Approved
DemecariumDemecarium may increase the bradycardic activities of Practolol.Approved
DeslanosidePractolol may increase the bradycardic activities of Deslanoside.Approved
DesvenlafaxineThe serum concentration of Practolol can be increased when it is combined with Desvenlafaxine.Approved
DexmedetomidineDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Practolol.Approved, Vet Approved
DichlorvosDichlorvos may increase the bradycardic activities of Practolol.Vet Approved
DiclofenacDiclofenac may decrease the antihypertensive activities of Practolol.Approved, Vet Approved
DifenpiramideDifenpiramide may decrease the antihypertensive activities of Practolol.Experimental
DiflunisalDiflunisal may decrease the antihypertensive activities of Practolol.Approved
DigitoxinPractolol may increase the bradycardic activities of Digitoxin.Approved, Investigational
DigoxinPractolol may increase the bradycardic activities of Digoxin.Approved
DihydroergotamineDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Practolol.Approved
DiltiazemDiltiazem may increase the hypotensive activities of Practolol.Approved
DipivefrinDipivefrin may increase the atrioventricular blocking (AV block) activities of Practolol.Approved
DipyridamoleDipyridamole may increase the bradycardic activities of Practolol.Approved
DisopyramideDisopyramide may increase the bradycardic activities of Practolol.Approved
DistigmineDistigmine may increase the bradycardic activities of Practolol.Experimental
DonepezilDonepezil may increase the bradycardic activities of Practolol.Approved
DoxazosinPractolol may increase the orthostatic hypotensive activities of Doxazosin.Approved
DronedaroneDronedarone may increase the bradycardic activities of Practolol.Approved
DroxicamDroxicam may decrease the antihypertensive activities of Practolol.Approved
DroxidopaDroxidopa may increase the atrioventricular blocking (AV block) activities of Practolol.Approved, Investigational
DuloxetineThe serum concentration of Practolol can be increased when it is combined with Duloxetine.Approved
DuvelisibDuvelisib may decrease the antihypertensive activities of Practolol.Investigational
E-6201E-6201 may decrease the antihypertensive activities of Practolol.Investigational
EchothiophateEchothiophate may increase the bradycardic activities of Practolol.Approved
EdrophoniumEdrophonium may increase the bradycardic activities of Practolol.Approved
EphedraEphedra may increase the atrioventricular blocking (AV block) activities of Practolol.Approved, Nutraceutical, Withdrawn
EpibatidineThe risk or severity of adverse effects can be increased when Practolol is combined with Epibatidine.Experimental
EpinephrineEpinephrine may increase the atrioventricular blocking (AV block) activities of Practolol.Approved, Vet Approved
EpirizoleEpirizole may decrease the antihypertensive activities of Practolol.Approved
Ergoloid mesylatePractolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
ErgonovinePractolol may increase the vasoconstricting activities of Ergonovine.Approved
ErgotamineErgotamine may increase the atrioventricular blocking (AV block) activities of Practolol.Approved
EtanerceptEtanercept may decrease the antihypertensive activities of Practolol.Approved, Investigational
EthenzamideEthenzamide may decrease the antihypertensive activities of Practolol.Experimental
EtodolacEtodolac may decrease the antihypertensive activities of Practolol.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the antihypertensive activities of Practolol.Approved, Investigational
EtomidateEtomidate may increase the atrioventricular blocking (AV block) activities of Practolol.Approved
EtoperidoneThe serum concentration of Practolol can be increased when it is combined with Etoperidone.Withdrawn
EtoricoxibEtoricoxib may decrease the antihypertensive activities of Practolol.Approved, Investigational
Evening primrose oilEvening primrose oil may decrease the antihypertensive activities of Practolol.Approved, Investigational
exisulindexisulind may decrease the antihypertensive activities of Practolol.Investigational
FelbinacFelbinac may decrease the antihypertensive activities of Practolol.Experimental
FenbufenFenbufen may decrease the antihypertensive activities of Practolol.Approved
FenoprofenFenoprofen may decrease the antihypertensive activities of Practolol.Approved
FentanylFentanyl may increase the bradycardic activities of Practolol.Approved, Illicit, Investigational, Vet Approved
FenthionFenthion may increase the bradycardic activities of Practolol.Vet Approved
FentiazacFentiazac may decrease the antihypertensive activities of Practolol.Experimental
FeprazoneFeprazone may decrease the antihypertensive activities of Practolol.Experimental
Ferulic acidFerulic acid may decrease the antihypertensive activities of Practolol.Experimental
FingolimodPractolol may increase the bradycardic activities of Fingolimod.Approved, Investigational
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Practolol.Approved, Withdrawn
FlunixinFlunixin may decrease the antihypertensive activities of Practolol.Vet Approved
FlunoxaprofenFlunoxaprofen may decrease the antihypertensive activities of Practolol.Experimental
FluoxetineThe serum concentration of Practolol can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FluphenazineFluphenazine may increase the hypotensive activities of Practolol.Approved
FlurbiprofenFlurbiprofen may decrease the antihypertensive activities of Practolol.Approved, Investigational
GalantamineGalantamine may increase the bradycardic activities of Practolol.Approved
Gallamine TriethiodideGallamine Triethiodide may increase the bradycardic activities of Practolol.Approved
Ginkgo bilobaGinkgo biloba may increase the bradycardic activities of Practolol.Approved, Investigational, Nutraceutical
GitoformatePractolol may increase the bradycardic activities of Gitoformate.Experimental
GlibornuridePractolol may increase the hypoglycemic activities of Glibornuride.Investigational, Withdrawn
GliclazidePractolol may increase the hypoglycemic activities of Gliclazide.Approved
GlipizidePractolol may increase the hypoglycemic activities of Glipizide.Approved
GliquidonePractolol may increase the hypoglycemic activities of Gliquidone.Approved, Investigational
GlisoxepidePractolol may increase the hypoglycemic activities of Glisoxepide.Approved, Investigational
GlyburidePractolol may increase the hypoglycemic activities of Glyburide.Approved
GTS-21The risk or severity of adverse effects can be increased when Practolol is combined with GTS-21.Investigational
GuacetisalGuacetisal may decrease the antihypertensive activities of Practolol.Experimental
GuanabenzGuanabenz may increase the atrioventricular blocking (AV block) activities of Practolol.Approved, Investigational
GuanfacineGuanfacine may increase the atrioventricular blocking (AV block) activities of Practolol.Approved, Investigational
HexobarbitalThe serum concentration of Practolol can be decreased when it is combined with Hexobarbital.Approved
HigenamineHigenamine may decrease the antihypertensive activities of Practolol.Investigational
Huperzine AHuperzine A may increase the bradycardic activities of Practolol.Investigational
HydroxychloroquineThe metabolism of Practolol can be decreased when combined with Hydroxychloroquine.Approved
IbuprofenIbuprofen may decrease the antihypertensive activities of Practolol.Approved
IbuproxamIbuproxam may decrease the antihypertensive activities of Practolol.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Practolol.Approved
Imidazole salicylateImidazole salicylate may decrease the antihypertensive activities of Practolol.Experimental
IndalpineThe serum concentration of Practolol can be increased when it is combined with Indalpine.Investigational, Withdrawn
IndobufenIndobufen may decrease the antihypertensive activities of Practolol.Investigational
IndomethacinIndomethacin may decrease the antihypertensive activities of Practolol.Approved, Investigational
IndoprofenIndoprofen may decrease the antihypertensive activities of Practolol.Withdrawn
IndoraminPractolol may increase the orthostatic hypotensive activities of Indoramin.Withdrawn
Insulin PorkPractolol may increase the hypoglycemic activities of Insulin Pork.Approved
IpidacrineIpidacrine may increase the bradycardic activities of Practolol.Experimental
IsoflurophateIsoflurophate may increase the bradycardic activities of Practolol.Approved, Investigational, Withdrawn
IsoxicamIsoxicam may decrease the antihypertensive activities of Practolol.Withdrawn
KebuzoneKebuzone may decrease the antihypertensive activities of Practolol.Experimental
KetoprofenKetoprofen may decrease the antihypertensive activities of Practolol.Approved, Vet Approved
KetorolacKetorolac may decrease the antihypertensive activities of Practolol.Approved
LabetalolPractolol may increase the orthostatic hypotensive activities of Labetalol.Approved
Lanatoside CPractolol may increase the bradycardic activities of Lanatoside C.Experimental
LeflunomideLeflunomide may decrease the antihypertensive activities of Practolol.Approved, Investigational
LevomilnacipranThe serum concentration of Practolol can be increased when it is combined with Levomilnacipran.Approved
LevonordefrinLevonordefrin may increase the atrioventricular blocking (AV block) activities of Practolol.Approved
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Practolol.Approved, Vet Approved
LisofyllineLisofylline may decrease the antihypertensive activities of Practolol.Investigational
LobelineThe risk or severity of adverse effects can be increased when Practolol is combined with Lobeline.Investigational
LofexidineLofexidine may increase the atrioventricular blocking (AV block) activities of Practolol.Approved, Investigational
LonazolacLonazolac may decrease the antihypertensive activities of Practolol.Experimental
LornoxicamLornoxicam may decrease the antihypertensive activities of Practolol.Approved, Investigational
LoxoprofenLoxoprofen may decrease the antihypertensive activities of Practolol.Approved, Investigational
LumiracoxibLumiracoxib may decrease the antihypertensive activities of Practolol.Approved, Investigational
Magnesium salicylateMagnesium salicylate may decrease the antihypertensive activities of Practolol.Approved
MalathionMalathion may increase the bradycardic activities of Practolol.Approved, Investigational
MasoprocolMasoprocol may decrease the antihypertensive activities of Practolol.Approved, Investigational
Meclofenamic acidMeclofenamic acid may decrease the antihypertensive activities of Practolol.Approved, Vet Approved
Mefenamic acidMefenamic acid may decrease the antihypertensive activities of Practolol.Approved
MefloquineMefloquine may increase the bradycardic activities of Practolol.Approved
MeloxicamMeloxicam may decrease the antihypertensive activities of Practolol.Approved, Vet Approved
MemantineMemantine may increase the bradycardic activities of Practolol.Approved, Investigational
MepivacaineThe serum concentration of Mepivacaine can be increased when it is combined with Practolol.Approved, Vet Approved
MesalazineMesalazine may decrease the antihypertensive activities of Practolol.Approved
MesoridazineMesoridazine may increase the hypotensive activities of Practolol.Approved, Investigational
MetahexamidePractolol may increase the hypoglycemic activities of Metahexamide.Experimental
MetamizoleMetamizole may decrease the antihypertensive activities of Practolol.Investigational, Withdrawn
MethacholineThe risk or severity of adverse effects can be increased when Practolol is combined with Methacholine.Approved
MethamphetamineMethamphetamine may increase the atrioventricular blocking (AV block) activities of Practolol.Approved, Illicit
Methanesulfonyl FluorideMethanesulfonyl Fluoride may increase the bradycardic activities of Practolol.Investigational
MethohexitalThe serum concentration of Practolol can be decreased when it is combined with Methohexital.Approved
MethotrimeprazineMethotrimeprazine may increase the hypotensive activities of Practolol.Approved
Methyl salicylateMethyl salicylate may increase the bradycardic activities of Practolol.Approved, Vet Approved
Methylene blueMethylene blue may increase the hypotensive activities of Practolol.Approved, Investigational
MethylergometrinePractolol may increase the vasoconstricting activities of Methylergometrine.Approved
MethylphenobarbitalThe serum concentration of Practolol can be decreased when it is combined with Methylphenobarbital.Approved
MetildigoxinPractolol may increase the bradycardic activities of Metildigoxin.Experimental
MetoclopramideMetoclopramide may increase the bradycardic activities of Practolol.Approved, Investigational
MidodrinePractolol may increase the bradycardic activities of Midodrine.Approved
MilnacipranThe serum concentration of Practolol can be increased when it is combined with Milnacipran.Approved
MinaprineMinaprine may increase the bradycardic activities of Practolol.Approved
MizoribineMizoribine may decrease the antihypertensive activities of Practolol.Investigational
MofebutazoneMofebutazone may decrease the antihypertensive activities of Practolol.Experimental
MoricizineMoricizine may increase the hypotensive activities of Practolol.Approved, Investigational, Withdrawn
MoxonidineMoxonidine may increase the atrioventricular blocking (AV block) activities of Practolol.Approved, Investigational
Mycophenolate mofetilMycophenolate mofetil may decrease the antihypertensive activities of Practolol.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the antihypertensive activities of Practolol.Approved
NabumetoneNabumetone may decrease the antihypertensive activities of Practolol.Approved
NafamostatNafamostat may decrease the antihypertensive activities of Practolol.Approved, Investigational
NaftifineNaftifine may decrease the antihypertensive activities of Practolol.Approved
NaphazolineNaphazoline may increase the atrioventricular blocking (AV block) activities of Practolol.Approved
NaproxenNaproxen may decrease the antihypertensive activities of Practolol.Approved, Vet Approved
NefazodoneThe serum concentration of Practolol can be increased when it is combined with Nefazodone.Approved, Withdrawn
NeostigmineNeostigmine may increase the bradycardic activities of Practolol.Approved, Vet Approved
NepafenacNepafenac may decrease the antihypertensive activities of Practolol.Approved
NicotineThe risk or severity of adverse effects can be increased when Practolol is combined with Nicotine.Approved
NifedipineNifedipine may increase the hypotensive activities of Practolol.Approved
NifenazoneNifenazone may decrease the antihypertensive activities of Practolol.Experimental
Niflumic AcidNiflumic Acid may decrease the antihypertensive activities of Practolol.Approved
NimesulideNimesulide may decrease the antihypertensive activities of Practolol.Approved, Investigational, Withdrawn
NitroaspirinNitroaspirin may decrease the antihypertensive activities of Practolol.Investigational
NorepinephrineNorepinephrine may increase the atrioventricular blocking (AV block) activities of Practolol.Approved
OleandrinPractolol may increase the bradycardic activities of Oleandrin.Experimental, Investigational
OlopatadineOlopatadine may decrease the antihypertensive activities of Practolol.Approved
OlsalazineOlsalazine may decrease the antihypertensive activities of Practolol.Approved
OrgoteinOrgotein may decrease the antihypertensive activities of Practolol.Vet Approved
OuabainPractolol may increase the bradycardic activities of Ouabain.Approved
OxaprozinOxaprozin may decrease the antihypertensive activities of Practolol.Approved
OxymetazolineOxymetazoline may increase the atrioventricular blocking (AV block) activities of Practolol.Approved
OxyphenbutazoneOxyphenbutazone may decrease the antihypertensive activities of Practolol.Approved, Withdrawn
PaliperidonePaliperidone may increase the atrioventricular blocking (AV block) activities of Practolol.Approved
ParaoxonParaoxon may increase the bradycardic activities of Practolol.Experimental
ParecoxibParecoxib may decrease the antihypertensive activities of Practolol.Approved
ParoxetineThe serum concentration of Practolol can be increased when it is combined with Paroxetine.Approved, Investigational
ParthenolideParthenolide may decrease the antihypertensive activities of Practolol.Investigational
PentobarbitalThe serum concentration of Practolol can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PerazinePerazine may increase the hypotensive activities of Practolol.Investigational
PergolidePergolide may increase the atrioventricular blocking (AV block) activities of Practolol.Approved, Investigational, Vet Approved, Withdrawn
PerphenazinePerphenazine may increase the hypotensive activities of Practolol.Approved
PeruvosidePractolol may increase the bradycardic activities of Peruvoside.Experimental
PhenobarbitalThe serum concentration of Practolol can be decreased when it is combined with Phenobarbital.Approved
PhenylbutazonePhenylbutazone may decrease the antihypertensive activities of Practolol.Approved, Vet Approved
PhenylpropanolaminePhenylpropanolamine may increase the atrioventricular blocking (AV block) activities of Practolol.Approved, Vet Approved, Withdrawn
PhysostigminePhysostigmine may increase the bradycardic activities of Practolol.Approved
PilocarpineThe risk or severity of adverse effects can be increased when Practolol is combined with Pilocarpine.Approved
PimecrolimusPimecrolimus may decrease the antihypertensive activities of Practolol.Approved, Investigational
PirfenidonePirfenidone may decrease the antihypertensive activities of Practolol.Approved, Investigational
PiroxicamPiroxicam may decrease the antihypertensive activities of Practolol.Approved, Investigational
PirprofenPirprofen may decrease the antihypertensive activities of Practolol.Experimental
PranoprofenPranoprofen may decrease the antihypertensive activities of Practolol.Experimental, Investigational
PrazosinPractolol may increase the orthostatic hypotensive activities of Prazosin.Approved
PrimaquineThe metabolism of Practolol can be decreased when combined with Primaquine.Approved
PrimidoneThe serum concentration of Practolol can be decreased when it is combined with Primidone.Approved, Vet Approved
ProchlorperazineProchlorperazine may increase the hypotensive activities of Practolol.Approved, Vet Approved
ProglumetacinProglumetacin may decrease the antihypertensive activities of Practolol.Experimental
PromazinePromazine may increase the hypotensive activities of Practolol.Approved, Vet Approved
PromethazinePromethazine may increase the hypotensive activities of Practolol.Approved
PropacetamolPropacetamol may decrease the antihypertensive activities of Practolol.Approved, Investigational
PropafenoneThe serum concentration of Practolol can be increased when it is combined with Propafenone.Approved
PropiopromazinePropiopromazine may increase the hypotensive activities of Practolol.Vet Approved
PropyphenazonePropyphenazone may decrease the antihypertensive activities of Practolol.Experimental
ProquazoneProquazone may decrease the antihypertensive activities of Practolol.Experimental
ProscillaridinPractolol may increase the bradycardic activities of Proscillaridin.Experimental
PseudoephedrinePseudoephedrine may increase the atrioventricular blocking (AV block) activities of Practolol.Approved
PTC299PTC299 may decrease the antihypertensive activities of Practolol.Investigational
PyridostigminePyridostigmine may increase the bradycardic activities of Practolol.Approved
RegorafenibRegorafenib may increase the bradycardic activities of Practolol.Approved
RemifentanilRemifentanil may increase the bradycardic activities of Practolol.Approved
ReserpineReserpine may increase the hypotensive activities of Practolol.Approved, Investigational
ResveratrolResveratrol may decrease the antihypertensive activities of Practolol.Approved, Experimental, Investigational
RifampicinThe serum concentration of Practolol can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Practolol can be decreased when it is combined with Rifapentine.Approved
RisperidoneRisperidone may increase the atrioventricular blocking (AV block) activities of Practolol.Approved, Investigational
RivastigmineRivastigmine may increase the bradycardic activities of Practolol.Approved, Investigational
RofecoxibRofecoxib may decrease the antihypertensive activities of Practolol.Investigational, Withdrawn
RopiniroleRopinirole may increase the atrioventricular blocking (AV block) activities of Practolol.Approved, Investigational
SalicylamideSalicylamide may decrease the antihypertensive activities of Practolol.Approved
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Practolol.Approved, Vet Approved
SalsalateSalsalate may decrease the antihypertensive activities of Practolol.Approved
SecobarbitalThe serum concentration of Practolol can be decreased when it is combined with Secobarbital.Approved, Vet Approved
SemapimodSemapimod may decrease the antihypertensive activities of Practolol.Investigational
SeratrodastSeratrodast may decrease the antihypertensive activities of Practolol.Approved
SerrapeptaseSerrapeptase may decrease the antihypertensive activities of Practolol.Investigational
SertralineThe serum concentration of Practolol can be increased when it is combined with Sertraline.Approved
SilodosinPractolol may increase the orthostatic hypotensive activities of Silodosin.Approved
SRT501SRT501 may decrease the antihypertensive activities of Practolol.Investigational
SufentanilSufentanil may increase the bradycardic activities of Practolol.Approved, Investigational
SulfasalazineSulfasalazine may decrease the antihypertensive activities of Practolol.Approved
SulindacSulindac may decrease the antihypertensive activities of Practolol.Approved
SuprofenSuprofen may decrease the antihypertensive activities of Practolol.Approved, Withdrawn
SuxibuzoneSuxibuzone may decrease the antihypertensive activities of Practolol.Experimental
TacrineTacrine may increase the bradycardic activities of Practolol.Investigational, Withdrawn
TamsulosinPractolol may increase the orthostatic hypotensive activities of Tamsulosin.Approved, Investigational
TarenflurbilTarenflurbil may decrease the antihypertensive activities of Practolol.Investigational
TenidapTenidap may decrease the antihypertensive activities of Practolol.Experimental
TenoxicamTenoxicam may decrease the antihypertensive activities of Practolol.Approved
TepoxalinTepoxalin may decrease the antihypertensive activities of Practolol.Vet Approved
TerazosinPractolol may increase the orthostatic hypotensive activities of Terazosin.Approved
TeriflunomideTeriflunomide may decrease the antihypertensive activities of Practolol.Approved
ThiamylalThe serum concentration of Practolol can be decreased when it is combined with Thiamylal.Approved, Vet Approved
ThiazinamThiazinam may increase the hypotensive activities of Practolol.Experimental
ThiethylperazineThiethylperazine may increase the hypotensive activities of Practolol.Withdrawn
ThiopentalThe serum concentration of Practolol can be decreased when it is combined with Thiopental.Approved, Vet Approved
ThioridazineThioridazine may increase the hypotensive activities of Practolol.Approved, Withdrawn
Tiaprofenic acidTiaprofenic acid may decrease the antihypertensive activities of Practolol.Approved
TinoridineTinoridine may decrease the antihypertensive activities of Practolol.Investigational
TizanidineTizanidine may increase the atrioventricular blocking (AV block) activities of Practolol.Approved
TolazamidePractolol may increase the hypoglycemic activities of Tolazamide.Approved
Tolfenamic AcidTolfenamic Acid may decrease the antihypertensive activities of Practolol.Approved
TolmetinTolmetin may decrease the antihypertensive activities of Practolol.Approved
TranilastTranilast may decrease the antihypertensive activities of Practolol.Approved, Investigational
TribenosideTribenoside may decrease the antihypertensive activities of Practolol.Experimental
TrichlorfonTrichlorfon may increase the bradycardic activities of Practolol.Vet Approved
TrifluoperazineTrifluoperazine may increase the hypotensive activities of Practolol.Approved
TriflupromazineTriflupromazine may increase the hypotensive activities of Practolol.Approved, Vet Approved
TrimazosinPractolol may increase the orthostatic hypotensive activities of Trimazosin.Experimental
TriptolideTriptolide may decrease the antihypertensive activities of Practolol.Investigational
TubocurarineTubocurarine may increase the bradycardic activities of Practolol.Approved
UrapidilPractolol may increase the orthostatic hypotensive activities of Urapidil.Investigational
ValdecoxibValdecoxib may decrease the antihypertensive activities of Practolol.Investigational, Withdrawn
VareniclineThe risk or severity of adverse effects can be increased when Practolol is combined with Varenicline.Approved, Investigational
VenlafaxineThe serum concentration of Practolol can be increased when it is combined with Venlafaxine.Approved
VerapamilVerapamil may increase the hypotensive activities of Practolol.Approved
XylometazolineXylometazoline may increase the atrioventricular blocking (AV block) activities of Practolol.Approved
ZaltoprofenZaltoprofen may decrease the antihypertensive activities of Practolol.Approved, Investigational
ZileutonZileuton may decrease the antihypertensive activities of Practolol.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Practolol can be increased when it is combined with Zimelidine.Withdrawn
ZomepiracZomepirac may decrease the antihypertensive activities of Practolol.Withdrawn
Food Interactions
  • Avoid alcohol.
  • Avoid natural licorice.

References

General References
Not Available
External Links
Human Metabolome Database
HMDB15411
KEGG Drug
D05587
KEGG Compound
C11696
PubChem Compound
4883
PubChem Substance
46507496
ChemSpider
4715
BindingDB
25749
ChEBI
258351
ChEMBL
CHEMBL6995
Therapeutic Targets Database
DAP000940
PharmGKB
PA164752820
Wikipedia
Practolol
ATC Codes
C07AB01 — Practolol

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)134-136 °CPhysProp
logP0.79HANSCH,C ET AL. (1995)
Caco2 permeability-6.05ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.49 mg/mLALOGPS
logP0.53ALOGPS
logP0.83ChemAxon
logS-2.7ALOGPS
pKa (Strongest Acidic)14.03ChemAxon
pKa (Strongest Basic)9.67ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area70.59 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity75.24 m3·mol-1ChemAxon
Polarizability30.39 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9472
Blood Brain Barrier-0.8609
Caco-2 permeable-0.8957
P-glycoprotein substrateSubstrate0.589
P-glycoprotein inhibitor INon-inhibitor0.8705
P-glycoprotein inhibitor IINon-inhibitor0.9147
Renal organic cation transporterNon-inhibitor0.9484
CYP450 2C9 substrateNon-substrate0.781
CYP450 2D6 substrateNon-substrate0.5082
CYP450 3A4 substrateNon-substrate0.6487
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorInhibitor0.6103
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.9289
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9268
Ames testNon AMES toxic0.9153
CarcinogenicityNon-carcinogens0.8402
BiodegradationNot ready biodegradable0.9564
Rat acute toxicity1.9187 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9917
hERG inhibition (predictor II)Non-inhibitor0.898
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-00dm-3900000000-6e93acc67e2905952d4e

Taxonomy

Description
This compound belongs to the class of organic compounds known as acetanilides. These are organic compounds containing an acetamide group conjugated to a phenyl group.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Anilides
Direct Parent
Acetanilides
Alternative Parents
N-acetylarylamines / Phenoxy compounds / Phenol ethers / Alkyl aryl ethers / Acetamides / Secondary carboxylic acid amides / Secondary alcohols / Amino acids and derivatives / 1,2-aminoalcohols / Dialkylamines
show 4 more
Substituents
Acetanilide / N-acetylarylamine / Phenoxy compound / N-arylamide / Phenol ether / Alkyl aryl ether / Acetamide / 1,2-aminoalcohol / Amino acid or derivatives / Carboxamide group
show 17 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
secondary alcohol, secondary amino compound, acetamides, ethanolamines, propanolamine (CHEBI:258351)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Receptor signaling protein activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately e...
Gene Name
ADRB1
Uniprot ID
P08588
Uniprot Name
Beta-1 adrenergic receptor
Molecular Weight
51322.1 Da
References
  1. Abrahamsson T: The beta 1- and beta 2-adrenoceptor stimulatory effects of alprenolol, oxprenolol and pindolol: a study in the isolated right atrium and uterus of the rat. Br J Pharmacol. 1986 Apr;87(4):657-64. [PubMed:2871880]
  2. Keyrilainen O, Uusitalo A: A comparative study of three beta 1-adrenoreceptor blocking drugs with different degree of intrinsic stimulating activity (metoprolol, practolol and H 87/07) in patients with angina pectoris. Ann Clin Res. 1978 Aug;10(4):185-90. [PubMed:30388]
  3. Saarnivaara L, Lindgren L, Hynynen M: Effects of practolol and metoprolol on QT interval, heart rate and arterial pressure during induction of anaesthesia. Acta Anaesthesiol Scand. 1984 Dec;28(6):644-8. [PubMed:6524278]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  5. Buxton IL, Brunton LL: Direct analysis of beta-adrenergic receptor subtypes on intact adult ventricular myocytes of the rat. Circ Res. 1985 Jan;56(1):126-32. [PubMed:2857116]

Drug created on June 30, 2007 08:19 / Updated on November 09, 2017 02:58